Immunomodulatory effects of fosfomycin in an endotoxin model in human blood

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 2, 2007, Pages 219-223

  Zeitlinger, Markus ^a   Marsik, Claudia ^a   Steiner, Ilka ^a   Sauermann, Robert ^a   Seir, Katja ^a   Jilma, Bernd ^a   Wagner, Oswald ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

In vitro; Sepsis; Whole blood

Indexed keywords

CYTOKINE; ENDOTOXIN; FOSFOMYCIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INCUBATION TIME; LEUKOCYTE; MALE; NORMAL HUMAN; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VOLUNTEER; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; SERUM BACTERICIDAL ACTIVITY;

ANTI-BACTERIAL AGENTS; BLOOD BACTERICIDAL ACTIVITY; ENDOTOXINS; FOSFOMYCIN; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; LEUKOCYTES; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947510737     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl464     Document Type: Article

References (26)

1. Takala A, Nupponen I, Kylanpaa-Back ML et al. Markers of inflammation in sepsis. Ann Med 2002; 34: 614-23.
2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
3. Parrillo JE, Parker MM, Natanson C et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-42.
4. Hoffman WD, Natanson C. Endotoxin in septic shock. Anesth Analg 1993; 77: 613-24.
5. Natanson C, Hoffman WD, Suffredini AF et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120: 771-83.
6. Carlet J. International Sepsis Forum. Immunological therapy in sepsis: currently available. Intensive Care Med 2001; 27 Suppl 1: S93-103.
7. Arndt P, Abraham E. Immunological therapy of sepsis: Experimental therapies. Intensive Care Med 2001; 27 Suppl 1: S104-15.
8. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3: 359-71.
9. Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or 'immuno-fairy tales'? Clin Microbiol Rev 2000; 13: 615-50.
10. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection 2005; 33 Suppl 2: 55-70.
11. Frossard M, Joukhadar C, Erovic BM et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 2000; 44: 2728-32.
12. Joukhadar C, Klein N, Dittrich P et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003; 51: 1247-52.
13. Matsumoto T, Tateda K, Miyazaki S et al. Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 1997; 41: 308-13.
14. Morikawa K, Watabe H, Araake M et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996; 40: 1366-70.
15. Matsumoto T, Tateda K, Miyazaki S et al. Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice. Antimicrob Agents Chemother 1999; 43: 697-8.
16. Behre G, Schedel I, Nentwig B et al. Endotoxin concentration in neutropenic patients with suspected Gram-negative sepsis: Correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother 1992; 36: 2139-46.
17. Marsik C, Halama T, Cardona F et al. Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock 2003; 20: 493-6.
18. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 1990; 93: 125-8.
19. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J Mol Endocrinol 2002; 29 23-39.
20. -ΔΔC(T) method. Methods 2001; 25: 402-8.
21. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101 1644-55.
22. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-78.
23. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290: 238-47.
24. Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-41.
25. Yoneshima Y, Ichiyama T, Ayukawa H et al. Fosfomycin inhibits NF-κB activation in U-937 and Jurkat cells. Int J Antimicrob Agents 2003; 21: 589-92.
26. Honda J, Okubo Y, Kusaba M et al. Fosfomycin (FOM: 1 R-2S-epoxypropylphosphonic acid) suppress the production of IL-8 from monocytes via the suppression of neutrophil function. Immunopharmacology 1998; 39: 149-55.